Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DSP-7888 in Pediatric Relapsed or Refractory High-Grade Gliomas
NCT02750891Phase 2Completed
- Sponsor
- Sumitomo Pharma
- Start
- Apr 2016
- Primary completion
- Jan 2020
- Countries
- 1
01
Overview
A Phase 2 trial of adegramotide + nelatimotide in glioblastoma (GBM), diffuse intrinsic pontine glioma (DIPG), glioma, sponsored by Sumitomo Pharma. Started Apr 2016; status: completed.
02
Drugs
adegramotide + nelatimotide
03
Conditions
glioblastoma (GBM)diffuse intrinsic pontine glioma (DIPG)glioma
Beyond the preview
Go deeper on NCT02750891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02750891.